BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Instructions to Adjust Work, Life, and Seeking after a Web based Advertising Degree - 2Germany sees third consecutive diesel price record after rule change
- 3Building a Flourishing Business: Illustrations from Business people
- 4The breakout star of NASA's Artemis 2 moon mission isn't an astronaut — it's the space toilet
- 5Land Rover Just Unveiled Its Dakar Rally Defender
- The most effective method to Pick the Right Material Organization: Your Definitive Aide
- IDF strikes Hamas terror cell operating near Israeli troops in northern Gaza
- EU Commission slams Israel's death penalty law for Palestinians
- Unsold Rams May Be Less expensive Than You Suspect
- AI’s errors may be impossible to eliminate – what that means for its use in health care
- Famous Versatile Brands: Your Decision
- 5 Destinations Where Airfare Is Dropping The Most For Spring 2026, Per Dollar Flight Club Analysis
- Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- Anti-war protests held across Israel under wartime gathering limits
